Zacks Investment Research downgraded shares of NuCana (NASDAQ:NCNA) from a hold rating to a sell rating in a report released on Thursday morning.

According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

NCNA has been the subject of a number of other reports. Cowen started coverage on shares of NuCana in a research note on Monday, October 23rd. They issued an outperform rating for the company. William Blair started coverage on shares of NuCana in a research note on Monday, October 23rd. They issued an outperform rating for the company. Citigroup started coverage on shares of NuCana in a research note on Monday, October 23rd. They issued a buy rating and a $23.00 price objective for the company. Finally, Jefferies Group started coverage on shares of NuCana in a research note on Monday, October 23rd. They issued a buy rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $21.00.

NuCana (NASDAQ NCNA) opened at $28.25 on Thursday. NuCana has a 52 week low of $9.32 and a 52 week high of $29.23.

Several large investors have recently modified their holdings of the business. Perceptive Advisors LLC purchased a new position in shares of NuCana in the 3rd quarter worth $3,674,000. Alyeska Investment Group L.P. bought a new stake in shares of NuCana in the 3rd quarter worth about $2,296,000. Citadel Advisors LLC bought a new stake in shares of NuCana in the 3rd quarter worth about $1,218,000. Sphera Funds Management LTD. bought a new stake in shares of NuCana in the 3rd quarter worth about $919,000. Finally, Baillie Gifford & Co. bought a new stake in shares of NuCana in the 3rd quarter worth about $8,266,000. 22.27% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “NuCana (NCNA) Cut to Sell at Zacks Investment Research” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/nucana-ncna-cut-to-sell-at-zacks-investment-research/1829414.html.

About NuCana

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.